George L․ Kumar, Senior Director at AstraZeneca, shared a post LinkedIn:
“From Whole-Body to Single Cell: A Triple-Reporter Mouse Model for In Vivo Cancer Imaging
How do you follow a tumor’s story from the whole animal all the way down to individual cells talking to each other? Most imaging models can’t – they’re built around a single technique that works at only one scale.
A new inducible triple-reporter mouse model (Rosa26LSL-NRL) changes that. It combines three complementary readouts in one system:
- Fluorescence – for high-resolution cellular detail
- Bioluminescence – for sensitive whole-body signal
- PET – for deep-tissue, quantitative imaging
Because it uses inducible Cre-lox control, researchers can switch reporter expression on with precise timing and tissue specificity – a key advantage for studying cancer as it actually develops.
Put to work in models of hepatocellular carcinoma and lung adenocarcinoma, the system tracked deep-tissue oncogenesis with whole-body bioluminescence and 18F tetrafluoroborate PET/MRI, then zoomed in with in situ microscopy to resolve cell–cell interactions inside the tumor microenvironment.
The result is genuinely multiscale, multimodal cell tracking – sensitive, tissue-specific, and spanning whole-body to cellular resolution in a single model. That kind of continuity is hard to overstate for anyone studying tumor evolution, metastatic spread, gene activation, or treatment response in vivo.
A powerful reminder that some of the biggest gains in cancer research come not from a single new technique, but from making existing ones speak to each other.”
Title: Multiscale in vivo imaging of tumor evolution using a germline conditional triple-reporter mouse
Authors: Ximena L. Raffo-Iraolagoitia, Abdullah Alyamani, Stephanie May, David Stevenson, Agata Mackintosh, Lynn McGarry, Jayanthi Anand, Dmitry Soloviev, Gavin Brown, Colin Nixon, Chrysa Kapeni, Maike De La Roche, Karen Blyth, Thomas Graham Bird, Douglas Strathdee, Scott K. Lyons, Gilbert Fruhwirth, Leo M. Carlin, David Y. Lewis
Read the Full Article.
Other articles featuring George L․ Kumar on OncoDaily.
